EDIT · Editas Medicine, Inc. · Webcasts, Transcripts & Audio
$1.70
-0.01 (-0.58%)
At close · Nov 20
Return incl. dividend (before tax)
Q2 2024 earnings call transcript
Market Cap
$263.92M
Shares
154.34M
Volume · Nov 19
1.93M
Avg daily vol (3M)
2.65M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Editas Medicine, Inc. Webcasts
Earnings calls, investor updates, investor days and conferences for Editas Medicine, Inc. (EDIT), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.
Pull transcripts and briefs through the earnings call transcript API or MCP →
Add these events to your calendar (.ics)
Earnings call
FY26 · Q3
2026-11-09
Editas Medicine, Inc. (EDIT) Q3 2026 Earnings Call
Revenue
$10.37M
▲ 37.4% YoY Diluted EPS
$-0.15
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-06-04
Editas Medicine, Inc. (EDIT) June 4, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-05-05
Editas Medicine, Inc. (EDIT) Q1 2026 Earnings Call
Revenue
$2.83M
▼ 39.2% YoY Diluted EPS
$-0.26
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-03-12
Editas Medicine, Inc. (EDIT) March 12, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY25 · Q4
2026-03-09
Editas Medicine, Inc. (EDIT) Q4 2025 Earnings Call
Revenue
$24.74M*
▼ 19.2% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-10
Editas Medicine, Inc. (EDIT) Q3 2025 Earnings Call
Revenue
$7.54M
▲ 12265.6% YoY Diluted EPS
$-0.28
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-09-02
Editas Medicine, Inc. (EDIT) Q2 2025 Earnings Call
Revenue
$3.58M
▲ 597.5% YoY Diluted EPS
$-0.63
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-12
Editas Medicine, Inc. (EDIT) Q1 2025 Earnings Call
Revenue
$4.66M
▲ 310.4% YoY Diluted EPS
$-0.92
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-01-13
Editas Medicine, Inc. (EDIT) Q4 2024 Earnings Call
Revenue
$30.61M*
▼ 49% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-04
Editas Medicine, Inc. (EDIT) Q3 2024 Earnings Call
Revenue
$61,000
▼ 98.9% YoY Diluted EPS
$-0.75
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-07
Editas Medicine, Inc. (EDIT) Q2 2024 Earnings Call Transcript
Positive tone
Reni-cel Clinical Progress (RUBY/EdiTHAL)
In-Vivo Gene Editing Pipeline
Enrollment and BLA Path
Revenue
$513,000
▼ 82.2% YoY Diluted EPS
$-0.82
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-08
Editas Medicine, Inc. (EDIT) Q1 2024 Earnings Call Transcript
Confident tone
Reni-cel clinical progress and enrollment
In vivo gene editing pipeline
Regulatory and BLA pathway
Revenue
$1.14M
▼ 88.5% YoY Diluted EPS
$-0.76
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-02-28
Editas Medicine, Inc. (EDIT) Q4 2023 Earnings Call Transcript
Confident tone
Reni-cel clinical development
FDA regulatory alignment
Enrollment and dosing progress
Revenue
$60.05M*
▲ 818.6% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-03
Editas Medicine, Inc. (EDIT) Q3 2023 Earnings Call Transcript
Revenue
$5.34M
▲ 12604.8% YoY Diluted EPS
$-0.55
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-02
Editas Medicine, Inc. (EDIT) Q2 2023 Earnings Call Transcript
Revenue
$2.89M
▼ 54.6% YoY Diluted EPS
$-0.56
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-05
Editas Medicine, Inc. (EDIT) Q1 2023 Earnings Call Transcript
Revenue
$9.85M
▲ 45.5% YoY Diluted EPS
$-0.71
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-02-22
Editas Medicine, Inc. (EDIT) Q4 2022 Earnings Call Transcript
Revenue
$6.54M*
▼ 47.6% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-02
Editas Medicine, Inc. (EDIT) Q3 2022 Earnings Call Transcript
Revenue
$42,000
▼ 99.3% YoY Diluted EPS
$-0.81
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-03
Editas Medicine, Inc. (EDIT) Q2 2022 Earnings Call Transcript
Revenue
$6.36M
▲ 1578.6% YoY Diluted EPS
$-0.78
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-04
Editas Medicine, Inc. (EDIT) Q1 2022 Earnings Call Transcript
Revenue
$6.77M
▲ 4.2% YoY Diluted EPS
$-0.74
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-02-24
Editas Medicine, Inc. (EDIT) Q4 2021 Earnings Call Transcript
Revenue
$12.47M*
▲ 9.2% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-08
Editas Medicine, Inc. (EDIT) Q3 2021 Earnings Call Transcript
Revenue
$6.20M
▼ 90.1% YoY Diluted EPS
$-0.57
▼ 575% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-08-04
Editas Medicine, Inc. (EDIT) Q2 2021 Earnings Call Transcript
Revenue
$379,000
▼ 96.5% YoY Diluted EPS
$-0.81
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-05-05
Editas Medicine, Inc. (EDIT) Q1 2021 Earnings Call Transcript
Revenue
$6.50M
▲ 13.6% YoY Diluted EPS
$-0.86
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-01-19
Editas Medicine, Inc. (EDIT) Q4 2020 Earnings Call Transcript
Revenue
$11.42M
▼ 7% YoY Diluted EPS
$-1.00
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-11-05
Editas Medicine, Inc. (EDIT) Q3 2020 Earnings Call Transcript
Revenue
$62.84M
▲ 1533.1% YoY Diluted EPS
$0.12
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-08-06
Editas Medicine, Inc. (EDIT) Q2 2020 Earnings Call Transcript
Revenue
$10.75M
▲ 361.3% YoY Diluted EPS
$-0.43
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-05-07
Editas Medicine, Inc. (EDIT) Q1 2020 Earnings Call Transcript
Revenue
$5.72M
▲ 176.6% YoY Diluted EPS
$-0.69
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-02-26
Editas Medicine, Inc. (EDIT) Q4 2019 Earnings Call
Revenue
$12.28M
▲ 100.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Showing 1–29 of 29 webcasts
Key facts
CIK
1650664
CUSIP
28106W103
13F (30d)
243 filings
207 filers
Visit website
Investor relations